Gilead Sciences (GILD) Receives EC Marketing Approval for Truvada in HIV-1 Risk Reduction
Tweet Send to a Friend
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for once-daily Truvada® (emtricitabine 200 mg/tenofovir ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
